Literature DB >> 25407048

Intravenous injections in neonatal mice.

Sara E Gombash Lampe1, Brian K Kaspar2, Kevin D Foust3.   

Abstract

Intravenous injection is a clinically applicable manner to deliver therapeutics. For adult rodents and larger animals, intravenous injections are technically feasible and routine. However, some mouse models can have early onset of disease with a rapid progression that makes administration of potential therapies difficult. The temporal (or facial) vein is just anterior to the ear bud in mice and is clearly visible for the first two days after birth on either side of the head using a dissecting microscope. During this window, the temporal vein can be injected with volumes up to 50 μl. The injection is safe and well tolerated by both the pups and the dams. A typical injection procedure is completed within 1-2 min, after which the pup is returned to the home cage. By the third postnatal day the vein is difficult to visualize and the injection procedure becomes technically unreliable. This technique has been used for delivery of adeno-associated virus (AAV) vectors, which in turn can provide almost body-wide, stable transgene expression for the life of the animal depending on the viral serotype chosen.

Entities:  

Mesh:

Year:  2014        PMID: 25407048      PMCID: PMC4353426          DOI: 10.3791/52037

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  24 in total

1.  Percutaneous intravenous injection in neonatal mice.

Authors:  M S Sands; J E Barker
Journal:  Lab Anim Sci       Date:  1999-06

2.  Bardet-Biedl syndrome.

Authors:  Elizabeth Forsythe; Philip L Beales
Journal:  Eur J Hum Genet       Date:  2012-06-20       Impact factor: 4.246

3.  Global gene transfer into the CNS across the BBB after neonatal systemic delivery of single-stranded AAV vectors.

Authors:  Noriko Miyake; Koichi Miyake; Motoko Yamamoto; Yukihiko Hirai; Takashi Shimada
Journal:  Brain Res       Date:  2011-03-31       Impact factor: 3.252

4.  Delivery of therapeutic agents through intracerebroventricular (ICV) and intravenous (IV) injection in mice.

Authors:  Jacqueline J Glascock; Erkan Y Osman; Tristan H Coady; Ferrill F Rose; Monir Shababi; Christian L Lorson
Journal:  J Vis Exp       Date:  2011-10-03       Impact factor: 1.355

5.  Intravenous administration of AAV2/9 to the fetal and neonatal mouse leads to differential targeting of CNS cell types and extensive transduction of the nervous system.

Authors:  Ahad A Rahim; Andrew M S Wong; Klemens Hoefer; Suzanne M K Buckley; Citra N Mattar; Seng H Cheng; Jerry K Y Chan; Jonathan D Cooper; Simon N Waddington
Journal:  FASEB J       Date:  2011-07-11       Impact factor: 5.191

6.  Therapeutic AAV9-mediated suppression of mutant SOD1 slows disease progression and extends survival in models of inherited ALS.

Authors:  Kevin D Foust; Desirée L Salazar; Shibi Likhite; Laura Ferraiuolo; Dara Ditsworth; Hristelina Ilieva; Kathrin Meyer; Leah Schmelzer; Lyndsey Braun; Don W Cleveland; Brian K Kaspar
Journal:  Mol Ther       Date:  2013-09-06       Impact factor: 11.454

7.  Neonatal gene transfer leads to widespread correction of pathology in a murine model of lysosomal storage disease.

Authors:  T M Daly; C Vogler; B Levy; M E Haskins; M S Sands
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

8.  Prevention of systemic clinical disease in MPS VII mice following AAV-mediated neonatal gene transfer.

Authors:  T M Daly; K K Ohlemiller; M S Roberts; C A Vogler; M S Sands
Journal:  Gene Ther       Date:  2001-09       Impact factor: 5.250

Review 9.  Juvenile neuronal ceroid lipofuscinoses.

Authors:  Shiyao Wang
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

10.  Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model.

Authors:  Yimin Hua; Kentaro Sahashi; Frank Rigo; Gene Hung; Guy Horev; C Frank Bennett; Adrian R Krainer
Journal:  Nature       Date:  2011-10-05       Impact factor: 49.962

View more
  16 in total

Review 1.  Humanized mice for immune checkpoint blockade in human solid tumors.

Authors:  Henry Yip; Carl Haupt; Grace Maresh; Xin Zhang; Li Li
Journal:  Am J Clin Exp Urol       Date:  2019-10-15

2.  In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration.

Authors:  Keiichiro Suzuki; Yuji Tsunekawa; Reyna Hernandez-Benitez; Jun Wu; Jie Zhu; Euiseok J Kim; Fumiyuki Hatanaka; Mako Yamamoto; Toshikazu Araoka; Zhe Li; Masakazu Kurita; Tomoaki Hishida; Mo Li; Emi Aizawa; Shicheng Guo; Song Chen; April Goebl; Rupa Devi Soligalla; Jing Qu; Tingshuai Jiang; Xin Fu; Maryam Jafari; Concepcion Rodriguez Esteban; W Travis Berggren; Jeronimo Lajara; Estrella Nuñez-Delicado; Pedro Guillen; Josep M Campistol; Fumio Matsuzaki; Guang-Hui Liu; Pierre Magistretti; Kun Zhang; Edward M Callaway; Kang Zhang; Juan Carlos Izpisua Belmonte
Journal:  Nature       Date:  2016-11-16       Impact factor: 49.962

3.  In Vivo Target Gene Activation via CRISPR/Cas9-Mediated Trans-epigenetic Modulation.

Authors:  Hsin-Kai Liao; Fumiyuki Hatanaka; Toshikazu Araoka; Pradeep Reddy; Min-Zu Wu; Yinghui Sui; Takayoshi Yamauchi; Masahiro Sakurai; David D O'Keefe; Estrella Núñez-Delicado; Pedro Guillen; Josep M Campistol; Cheng-Jang Wu; Li-Fan Lu; Concepcion Rodriguez Esteban; Juan Carlos Izpisua Belmonte
Journal:  Cell       Date:  2017-12-07       Impact factor: 41.582

4.  Methods and Tips for Intravenous Administration of Adeno-associated Virus to Rats and Evaluation of Central Nervous System Transduction.

Authors:  Mychal S Grames; Kasey L Jackson; Robert D Dayton; John A Stanford; Ronald L Klein
Journal:  J Vis Exp       Date:  2017-08-25       Impact factor: 1.355

5.  Intracerebroventricular and Intravascular Injection of Viral Particles and Fluorescent Microbeads into the Neonatal Brain.

Authors:  Hideya Kawasaki; Isao Kosugi; Makiko Sakao-Suzuki; Shiori Meguro; Yoshihiro Tsutsui; Toshihide Iwashita
Journal:  J Vis Exp       Date:  2016-07-24       Impact factor: 1.355

6.  Impeding Transcription of Expanded Microsatellite Repeats by Deactivated Cas9.

Authors:  Belinda S Pinto; Tanvi Saxena; Ruan Oliveira; Héctor R Méndez-Gómez; John D Cleary; Lance T Denes; Ona McConnell; Juan Arboleda; Guangbin Xia; Maurice S Swanson; Eric T Wang
Journal:  Mol Cell       Date:  2017-10-19       Impact factor: 17.970

7.  Systemic administration of AAV-Slc25a46 mitigates mitochondrial neuropathy in Slc25a46-/- mice.

Authors:  Li Yang; Jesse Slone; Zhuo Li; Xiaoting Lou; Yueh-Chiang Hu; Luis F Queme; Michael P Jankowski; Taosheng Huang
Journal:  Hum Mol Genet       Date:  2020-03-13       Impact factor: 6.150

8.  Correction of metabolic abnormalities in a mouse model of glycogen storage disease type Ia by CRISPR/Cas9-based gene editing.

Authors:  Irina Arnaoutova; Lisa Zhang; Hung-Dar Chen; Brian C Mansfield; Janice Y Chou
Journal:  Mol Ther       Date:  2020-12-23       Impact factor: 11.454

9.  Full-length dystrophin restoration via targeted exon integration by AAV-CRISPR in a humanized mouse model of Duchenne muscular dystrophy.

Authors:  Adrian Pickar-Oliver; Veronica Gough; Joel D Bohning; Siyan Liu; Jacqueline N Robinson-Hamm; Heather Daniels; William H Majoros; Garth Devlin; Aravind Asokan; Charles A Gersbach
Journal:  Mol Ther       Date:  2021-09-10       Impact factor: 12.910

10.  Intravenous AAV9 efficiently transduces myenteric neurons in neonate and juvenile mice.

Authors:  Sara E Gombash; Christopher J Cowley; Julie A Fitzgerald; Jodie C E Hall; Christian Mueller; Fedias L Christofi; Kevin D Foust
Journal:  Front Mol Neurosci       Date:  2014-10-15       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.